Arrowhead Pharmaceuticals (ARWR) Capital Leases (2011 - 2016)

Arrowhead Pharmaceuticals (ARWR) has 6 years of Capital Leases data on file, last reported at $378862.0 in Q2 2016.

• Quarterly Capital Leases fell 36.38% year-over-year to $378862.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $378862.0 (down 36.38% YoY) and the FY2015 annual result came in at $540792.0, down 28.69% from the prior year.
• Capital Leases retreated to $378862.0 in Q2 2016, from $430665.0 in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $1.4 million in Q1 2012 to a low of $378862.0 in Q2 2016.
• A 5-year average of $878776.7 and a median of $838973.0 in 2014 frame the typical range for Capital Leases.
• Annual changes were most pronounced in 2012 — Capital Leases dropped 15.0% — and 2016, when it sank 36.38%.
• Tracing ARWR's Capital Leases over 5 years: stood at $1.2 million in 2012, then decreased by 18.03% to $1.0 million in 2013, then decreased by 29.93% to $705173.0 in 2014, then plunged by 31.1% to $485842.0 in 2015, then dropped by 22.02% to $378862.0 in 2016.
• The last three Capital Leases figures came in at $378862.0 (Q2 2016), $430665.0 (Q1 2016), and $485842.0 (Q4 2015), per Business Quant data.